Skip to main content
Shanghai Bao Pharmaceuticals Co., Ltd. logo

Shanghai Bao Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 2659 HKEX Manufacturing
Open in API
Filings indexed 33 across all filing types
Latest filing 2025-08-21 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2659

About Shanghai Bao Pharmaceuticals Co., Ltd.

https://www.baopharma.com

Shanghai Bao Pharmaceuticals Co., Ltd., established in 2019, is an innovative biotechnology company focused on the clinical development, industrialization, and commercialization of recombinant protein and antibody-based therapeutics. The company leverages synthetic biology technology and its proprietary subcutaneous (SC) drug delivery platform, Hysorptase, to advance novel biologic candidates. Shanghai Bao maintains a diverse clinical pipeline and has an approved product. Its portfolio includes finished dosage forms such as injectable solutions, lyophilized powder injections, and pre-filled syringes. A key product, Ricefidase (KJ103) Recombinant IgG Cleaving Enzyme, is developed to meet the clinical needs of patients suffering from acute and severe autoimmune diseases, organ transplant recipients, and individuals requiring gene therapy.

Recent filings

Filing Released Lang Actions
OC Announcement - Appointment
Share Issue/Capital Change Classification · 1% confidence The document is a mandatory Stock Exchange of Hong Kong announcement under Listing Rule 12.01C, disclaiming that it is not a prospectus and stating that the Company has appointed overall coordinators for its proposed public offering and Hong Kong listing. This is an announcement related to a new share issue rather than a full prospectus or a management report, fitting the definition of a Share Issue/Capital Change filing.
2025-08-21 English
Application Proof (1st submission)
Regulatory Filings Classification · 1% confidence The document is an 'Application Proof' for an IPO on the Hong Kong Stock Exchange (HKEX). It contains a list of links to various sections of a prospectus, such as 'Industry Overview', 'Business', 'Financial Information', and 'Accountants' Report'. Since this is a landing page or index providing access to the various components of a formal IPO prospectus filing, it functions as a Report Publication Announcement (RPA) for the regulatory filing of the application proof.
2025-08-21 English
Application Proof (1st submission)
Share Issue/Capital Change Classification · 1% confidence The document is an extensive ‘‘Application Proof’’ (draft prospectus) for Shanghai Bao Pharmaceuticals Co., Ltd.’s initial public offering on the Hong Kong Stock Exchange. It is not a brief announcement or a simple regulatory notice; it is the full offering document detailing the number of shares, pricing range, underwriting arrangements, risk factors, financial information, etc. It is therefore directly related to a new share issuance and the associated capital change. The closest category in our taxonomy for a prospectus of this nature is ‘‘Share Issue/Capital Change’’ (SHA).
2025-08-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.